IRDS

The IEEE International Roadmap for Devices and Systems (IRDS) Emerges as a Global Leader for Chips Acts Visions and Programs

Retrieved on: 
Tuesday, December 12, 2023
SCR, 3DIC, Ecosystem, METI, European Chips Act, Multilateralism, Balestra, ITRS, Organization, International, Provinces of Greece, LOS, TFRC, IRC, Society, Ministry, IRDS, TIA, Keio University, Nanoelectronics, Siemens Digital Industries Software, NIST, ICOS, MOU, Device, IEEE, NSTC, WSC, IRCS, Electronics, IEEE CS, TSMC, Faculty, IAC, Task force, Visiting scholar, Consumer electronics, Mobile phone, Science, System, Semiconductor

LOS ALAMITOS, Calif., Dec. 12, 2023 /PRNewswire/ --The broad utilization of the IEEE International Roadmap for Devices and Systems (IRDS) is influencing the various Chips Acts worldwide.

Key Points: 
  • LOS ALAMITOS, Calif., Dec. 12, 2023 /PRNewswire/ --The broad utilization of the IEEE International Roadmap for Devices and Systems (IRDS) is influencing the various Chips Acts worldwide.
  • Initiatives in Europe, Japan, and the US are engaging the IRDS roadmap for guidance as their activities develop, said Tom Coughlin, President of IEEE.
  • IEEE International Roadmap for Devices and Systems maps the future for microelectronics industry.
  • The SiNANO Institute , European Academic and Scientific Association for Nanoelectronics and the Systems and Devices Roadmap of Japan (SDRJ) are founding members of IRDS.

Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases

Retrieved on: 
Wednesday, December 28, 2022
Ghent University Hospital, Severe cognitive impairment, Therapy, RESEARCH, Medical genetics, Louise Ivers, AAV, Ghent University, Epithelium, Retinal pigment epithelium, BEST1, Division, IRDS, Growth, Patient, Raymond, Retina, Genetics, Retinal degeneration, PARK, Doctor of Philosophy, Pharmaceutical industry, MD, EU, Opus, Ophthalmology, IND

RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), respectively.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio.
  • Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), respectively.
  • The BEST1 gene therapy is designed to deliver a functional copy of the BEST1 gene to retinal pigment epithelial cells to produce bestrophin-1 protein and normalize homeostasis between the photoreceptors and retinal pigment epithelial cells.
  • Iveric retains certain rights with respect to the potential future commercialization of gene therapy products for BEST1 and/or RHO-adRP under certain circumstances.

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

Retrieved on: 
Thursday, December 1, 2022
Science, FIH, Professor, DSMB, RCD, Natural history, ANSM, Food, University, DNA, Epistasis, Gene, IND, University of Pittsburgh Medical Center, Safety, PDE6B, Toys "R" Us, Inc. v. Step Two, S.A, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PDE6A, Retina, Retinitis pigmentosa, Disease, RHO, CTA, IRD, AMD, Research, Quality of life, Severe cognitive impairment, Data monitoring committee, Oxidative stress, AAV, FDA, IRDS, Pharmaceutical industry, Vaccine, RP

SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.

Key Points: 
  • SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.
  • First safety data are anticipated in 2023 and the primary endpoint is expected to be reached in 2025.
  • With over 80 genes involved in RP, each with numerous causative mutations, we need to go beyond the gene-by-gene treatment approach.
  • SPVN06 has the potential to become the universal therapeutic solution that patients need, and we are excited for the next phase of development.

Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases

Retrieved on: 
Monday, November 14, 2022
AAV, Retinal degeneration, PARK, Severe cognitive impairment, RESEARCH, Ophthalmology, RDH12, Retina, Science, Triangle Park (Quezon City), Research, IRDS, Retinal dehydrogenase, IRD, Visual impairment, Natural history, Organization, Genetics, Gene, Patient, Pharmaceutical industry, Opus

RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the company will co-sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the company will co-sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs).
  • Opus is building a strong portfolio of programs focused on treating genetic mutations that cause inherited retinal diseases.
  • The natural history data collected as part of the Foundations Uni-Rare Study, a first of its kind in retinal diseases, will be critical to the future research and development of new therapies for inherited retinal diseases.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.

Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes

Retrieved on: 
Thursday, November 10, 2022
IRDS, RPE65, Retina, Macular degeneration, Research, Gene, Population, Ophthalmology, Therapy, Nanoparticle, USH2A, Severe cognitive impairment, Company, CEP290, Genetics, University of Pittsburgh School of Medicine, Foundation Fighting Blindness, Wilfrid Sellars, USH1B, Environment, MYO7A, Doctor of Pharmacy, Triangle Park (Quezon City), CNGA3, AAV, Science, Patient, CEO, RHO, CNGB3, MD, RPGR, Doctor of Philosophy, Research Triangle, Foundation, HIV disease progression rates, Retinitis pigmentosa, CHM, Biotechnology, Retinal degeneration, Leber congenital amaurosis, PROM1, IRD, Technology, RDH12, Usher syndrome, PCDH15, University, Visual impairment, Atsena Otie Key, MBA, LCA, Natural history, Pharmaceutical industry, Medical device, Vaccine, Antibiotics, Opus, GUCY2D

COLUMBIA, Md., Nov. 10, 2022 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, is committing at least $8.6 million for its Uni-Rare Study, a new natural history study for approximately 1,500 people with one of more than 300 rare genes associated with inherited retinal diseases (IRDs) including: retinitis pigmentosa, Leber congenital amaurosis, Usher syndrome, and a broad range of other conditions.

Key Points: 
  • "A majority of the 300 genes linked to inherited retinal diseases have not been well characterized in the clinic.
  • "We are excited to launch a highly inclusive study to benefit a large segment of the population affected by IRDs, which are so genetically diverse."
  • Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, November 3, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Optical, Other Science, Science, Patient, Company, ACP, Private Securities Litigation Reform Act, AMD, Hercules, Research, International, Sale, Food, Society, American Academy, ISEE, Regulation of tobacco by the U.S. Food and Drug Administration, OLE, European Medicines Agency, FDA, Silicon Valley Bank, Population, D, Safety, Investor, SVB, STAR, Nasdaq, NDA, Organization, Annual general meeting, Physician, U.S. Securities and Exchange Commission, Clinical trial, Forward-looking statement, MAA, Acquisition, Program, Security (finance), Stargardt disease, Geographic atrophy, IRDS, Pharmaceutical industry, Bank, Air cargo, Retina, MD

IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update.
  • The GATHER2 topline results for ACP were presented in two oral sessions as part of the Retina Subspecialty Day at the American Academy of Ophthalmology 2022 Annual Meeting on September 30, 2022.
  • Iveric Bio will host a conference call/webcast to discuss the Companys financial and operating results and provide a business update.
  • A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com .

Syncona to Acquire Applied Genetic Technologies Corporation

Retrieved on: 
Monday, October 24, 2022
Therapy, IRDS, ACHM, CVR, Failure, CVR Partners, Retina, Optogenetics, Achievement, Person, LON, TIME, Money transmitter, Schedule TO, GLOBE, Central nervous system, Risk, Review, Hand, EACH, Security (finance), Technology, Goal, AAV, Cyprus Securities and Exchange Commission, Applied Genetic Technologies Corporation, CNS, Schedule, Central nervous system disease, SEC, Life, COMMON, Patient, Letter of transmittal, Neurotology, Nasdaq, Partnership, Exercise, P.C, Letter, Cryptocurrency, Pharmaceutical industry, Syncona

We share AGTCs passion in developing life changing treatments for patients with diseases with no currently approved therapies, said Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited.

Key Points: 
  • We share AGTCs passion in developing life changing treatments for patients with diseases with no currently approved therapies, said Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited.
  • Syncona has significant expertise in AAV gene therapy, and in particular, a strong track record of building retinal gene therapy businesses.
  • Under the terms of the definitive agreement, an indirect subsidiary of Syncona Limited will initiate a tender offer to acquire all outstanding shares of AGTC common stock.
  • Applied Genetic Technologies Corporation Contacts:

Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001

Retrieved on: 
Wednesday, September 21, 2022
Dai, Lists of diseases, Safety, Center for Drug Evaluation and Research, IRD, U.S. FDA, AAV, FDA, Food, Center, Visual impairment, Retinal degeneration (rhodopsin mutation), Ophthalmology, RPE65, RPE, Hematology, Occult macular dystrophy, Therapy, CDE, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, CEO, Severe cognitive impairment, Retinal pigment epithelium, Neurology, CNS, Research, GLOBE, NMPA, Mutation, GMP, IRDS, Pharmaceutical industry, IND

Frontera previously announced that the U.S. Food and Drug Administration (FDA) also cleared an IND for FT-001 earlier this year in April.

Key Points: 
  • Frontera previously announced that the U.S. Food and Drug Administration (FDA) also cleared an IND for FT-001 earlier this year in April.
  • Inherited retinal degenerations or dystrophies are a heterogenous group of serious eye conditions that cause visual impairment that may lead to blindness.
  • This year, we have advanced our lead program, FT-001, and have received both U.S. FDA and China CDE IND clearances.
  • For additional information about Frontera Therapeutics, please visit the companys website at www.fronteratherapeutics.com .

RD Fund Participates in a €75 Million Series B for SparingVision

Retrieved on: 
Thursday, September 15, 2022
RP, Retinitis pigmentosa, Therapy, Foundation Fighting Blindness, Disease, Intellia Therapeutics, Retina, Usher syndrome, Patient, MBA, Visual acuity, Severe cognitive impairment, Doctor of Philosophy, Foundation, Macular degeneration, Research, Genome, IRDS, Color, Visual impairment, Pharmaceutical industry, Antibiotics

RALEIGH, N.C., Sept. 15, 2022 /PRNewswire/ -- Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases – announces its participation in a €75 million Series B financing for SparingVision. The round was co-led by Jeito Capital and UPMC Enterprises, with participation from 4BIO Capital, Bpifrance, Ysios Capital, and the RD Fund.

Key Points: 
  • RALEIGH, N.C., Sept. 15, 2022 /PRNewswire/ -- Today, the RD Fund (Retinal Degeneration Fund) the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases announces its participation in a 75 million Series B financing for SparingVision .
  • The round was co-led by Jeito Capital and UPMC Enterprises , with participation from 4BIO Capital, Bpifrance , Ysios Capital, and the RD Fund.
  • SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
  • "Our investment reflects the long-term funding and investment strategies of the Foundation and the RD Fund to bring forward a pipeline of novel therapeutics, including SparingVision's genetic medicines," said Rusty Kelley, PhD, MBA, managing director, RD Fund and SparingVision board director.

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Retrieved on: 
Wednesday, September 14, 2022
Retinitis pigmentosa, RP, Retina, Outline of health sciences, Foundation Fighting Blindness, Twitter, UPMC, Stargardt disease, CRISPR, University of Pittsburgh School of Medicine, Intellia Therapeutics, LinkedIn, Company, Gene, Growth, Therapy, Severe cognitive impairment, Usher syndrome, Patient, Investment, The New England Journal of Medicine, Cell, Nature, Solution, Foundation, Science, NASDAQ, Do Meu Jeito, Macular degeneration, Research, University, Mutation, Genome, IRDS, Visual impairment, NTLA, Pharmaceutical industry, Lancet

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.

Key Points: 
  • SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
  • Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the worlds most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs).
  • The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.
  • Inherited retinal diseases are a group of progressive eye conditions that can cause severe vision loss and, in certain cases, lead to total blindness.